VivoSeq
Cardiovascular

Coronary Artery Bypass Graft

4

Pipeline Programs

2

Active Trials

3

Companies Involved

Coronary Artery Bypass Graft is an early-stage landscape with 4 programs across 3 companies. The most active players are Metro International Biotech, LLC, Merck & Co., Omnivium. 3 therapies are approved.

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

11/100

Mech. Concentration

50/100

Completion Rate

75/100

Attrition Rate

0/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

Trial Status

6

clinical trials

Completed3 · 50%
Suspended1 · 17%
Recruiting1 · 17%
Active, not recruiting1 · 17%

Trial Activity

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)